aTYR PHARMA (ATYR) EBT Growth (3y) (2017 - 2026)
Powered by 
Analysis
aTYR PHARMA (ATYR) EBT Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 19.70% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -103.74% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.22% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 12.16% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 24.03% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 103.79% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 38.36% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -42.82% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 7.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.27% |
| Mar 31, 2026 | 3.01% |
| Dec 31, 2025 | -23.01% |
| Sep 30, 2025 | -26.06% |
| Jun 30, 2025 | -17.16% |
| Mar 31, 2025 | -7.06% |
| Dec 31, 2024 | -21.44% |
| Sep 30, 2024 | -32.86% |
| Jun 30, 2024 | -18.36% |
| Mar 31, 2024 | -32.33% |
| Dec 31, 2023 | -47.83% |
| Sep 30, 2023 | -24.66% |
| Jun 30, 2023 | -29.32% |
| Mar 31, 2023 | -106.66% |
| Dec 31, 2022 | -10.07% |
| Sep 30, 2022 | -34.41% |
| Jun 30, 2022 | -30.90% |
| Mar 31, 2022 | -30.02% |
| Dec 31, 2021 | -13.98% |
| Sep 30, 2021 | -5.18% |